Shares of Moderna, Inc. (MRNA) rose 4.37% to $57.55 after the company announced the launch of human testing for its Bundibugyo Ebola vaccine candidate, mRNA-1469, in Canada. The first participants have been vaccinated following authorization from Health Canada for the Phase 1 study.

First Human Trial for mRNA-1469 Underway

Moderna initiated the study at three Canadian clinical sites. Researchers will evaluate the safety, tolerability, and immune responses of mRNA-1469 among healthy adult volunteers. The trial aims to enroll approximately 80 participants during its first stage.

The vaccine candidate was developed on the same messenger RNA platform used in Moderna's COVID-19 vaccines, a technology that allows researchers to design and produce new vaccine candidates more rapidly than traditional platforms once a pathogen's genetic sequence is identified. The company also drew on prior research into filoviruses and related Ebola strains, which facilitated the candidate's progression from laboratory development to clinical evaluation.

This trial represents the first human assessment of a Moderna vaccine targeting Bundibugyo ebolavirus disease. No licensed vaccine currently exists to protect against illness caused by this specific virus. The only FDA-approved Ebola vaccine, Merck's Ervebo, along with Janssen's two-dose Zabdeno/Mvabea regimen, targets Zaire ebolavirus, which is genetically distinct from the Bundibugyo strain driving the current outbreak. That gap leaves no authorized countermeasure for Bundibugyo-specific protection.

CEPI Commits Up to $50 Million

The Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership established in 2017 to develop vaccines against emerging infectious disease threats, has committed up to $50 million to support preclinical work and the Phase 1 study. The partnership also funds the production of additional clinical doses during early development, a structure designed to shorten preparation time for larger trials should initial results prove favorable.

Moderna intends to use Phase 1 findings to inform potential Phase 2 and Phase 3 trials. Because manufacturing efforts will continue in parallel with clinical research, the company expects it can scale up testing rapidly. Future development phases, however, remain contingent upon safety and immune response data.

The agreement includes supply commitments for countries with limited vaccine access. Moderna will reserve at least 500,000 doses for lower-income and middle-income markets and plans to offer them under access pricing following any regulatory approval.

Congo Outbreak Underscores Urgent Need

Bundibugyo ebolavirus is driving the active outbreak in the Democratic Republic of the Congo. Health authorities have reported more than 3,000 confirmed cases and over 1,400 deaths, placing the outbreak among the largest filovirus emergencies ever recorded worldwide.

The World Health Organization has declared a Public Health Emergency of International Concern, and Africa CDC has declared a Public Health Emergency of Continental Security. Both determinations reflect the outbreak's scale, transmission speed, and growing regional risk.

The Canadian trial provides health agencies with another potential tool against the outbreak strain, though Moderna must still complete clinical testing before regulators can consider approval. The program also strengthens the company's broader infectious disease pipeline, which includes candidates for respiratory syncytial virus, cytomegalovirus, and influenza, as Moderna works to expand its portfolio beyond COVID-19 vaccines.